Published online Apr 26, 2020. doi: 10.4330/wjc.v12.i4.123
Peer-review started: October 26, 2019
First decision: November 19, 2019
Revised: January 18, 2020
Accepted: March 12, 2020
Article in press: March 12, 2020
Published online: April 26, 2020
Processing time: 178 Days and 20.3 Hours
Core tip: Nav1.8 has been implicated by multiple studies in producing the late sodium current, predisposing the cardiomyocyte to arrhythmogenic activity. Animal models have demonstrated an enhancement of this aberrant current in aged hearts. Human studies have identified a reduction of Nav1.5 and an increase in Nav1.8 in both heart failure and left ventricular hypertrophy, strongly suggesting that voltage-gated sodium channel expression plays a central role in the development of arrhythmia. Clinically, sodium channel blockade through Ranolazine has proved promising in terminating the arrhythmia. Prevention of atrial fibrillation should focus on lifestyle management, as well as targeting cardiac risk factors. Irbesartan has been demonstrated to slow atrial remodelling, prevent atrial fibrillation in animal models, as well as avert the arrhythmia in human subjects.
